Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride

Current Medical Research and Opinion
Philippe Nuss, Cédric Tessier


Restoration of quality of life is considered as the ultimate treatment goal in the management of schizophrenia and is important for destigmatising the disease. However, few studies, including the most recent, have collected quality of life data prospectively or evaluated the relationship of treatment with quality of life. Amisulpride is an atypical antipsychotic drug which has been described to have potency in improving negative symptoms of chronic schizophrenia and whose use is associated with a relatively low rate of emergence of extrapyramidal side-effects. These properties may contribute to a beneficial effect on quality of life. A systematic literature review of functional outcome in clinical trials with amisulpride was performed in order to assess the effect of this drug on quality of life and social functioning in patients. The Medline database was searched for all studies of amisulpride in schizophrenia which reported functional and quality of life outcomes up until 30 September 2009. Only one dedicated study assessing functional outcome or quality of life as a primary outcome criterion was identified. This demonstrated significant improvement in subjective well-being in patients with schizophrenia initiating treatment ...Continue Reading


Sep 1, 1992·The American Journal of Psychiatry·H H GoldmanT R Lave
Aug 1, 1990·Hospital & Community Psychiatry·H Y MeltzerL F Ramirez
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Sep 1, 1984·Canadian Journal of Psychology·R W Heinrichs
May 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·S H JonesG Dunn
Sep 1, 1995·International Clinical Psychopharmacology·A G AwadR J Heslegrave
Jan 1, 1997·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A G AwadR J Heslegrave
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
Aug 12, 1999·The International Journal of Social Psychiatry·S PriebeS Evans
Oct 14, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P CarrièreT Lempérière
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
May 18, 2001·Schizophrenia Research·C TekR W Buchanan
Aug 9, 2001·Annals of Medicine·R Rabin, F de Charro
Jan 25, 2002·International Clinical Psychopharmacology·P SaleemH Loo
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling
Jun 12, 2002·CNS Drugs·Jonathan S E Hellewell
Jul 20, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J PeuskensA Puech
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel SechterUNKNOWN Amisulpride Study Group
Apr 16, 2003·Schizophrenia Bulletin·Jitschak G StorosumAndré W Broekmans
Apr 13, 2004·International Clinical Psychopharmacology·Ann MortimerUNKNOWN SOLIANOL Sudy Group
Jun 17, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·A George Awad, Lakshmi N P Voruganti
Nov 4, 2004·CNS Drugs·Kate McKeage, Greg L Plosker
Mar 26, 2005·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Anita Bengtsson-TopsThomas Middelboe
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Simon SurguladzeMichael J Travis
Jul 16, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Pascal DelamillieureSonia Dollfus
Aug 2, 2005·Schizophrenia Research·W Wolfgang FleischhackerUNKNOWN EUFEST Steering Committee
Sep 17, 2005·Scottish Medical Journal·M TaylorK Fraser
Feb 7, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·J BobesM Bousoño
Mar 11, 2006·International Clinical Psychopharmacology·Jean-Pierre OliéRuoyong Yang
Nov 18, 2006·Journal of Clinical Psychopharmacology·Josep Maria HaroUNKNOWN SOHO Study Group
Nov 23, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·J-M Vanelle, S Douki
May 1, 2007·Schizophrenia Research·Dirk HeiderMondher Toumi
May 3, 2007·The International Journal of Social Psychiatry·Ann M Mortimer, Ahmed Omar Ahmed Al-Agib
Sep 1, 2007·Social Psychiatry and Psychiatric Epidemiology·Yvette KuselTom Burns
Feb 16, 2008·The Journal of Nervous and Mental Disease·Steven MarwahaUNKNOWN EuroSC Study Group
Sep 10, 2008·Psychiatry and Clinical Neurosciences·Ken YamauchiTetsuro Ohmori
Nov 1, 2008·Social Psychiatry and Psychiatric Epidemiology·Carin J MeijerAart H Schene

❮ Previous
Next ❯


Dec 12, 2012·Indian Journal of Psychiatry·Amresh ShrivastavaNilesh Shah
May 14, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanWilliam P Horan
May 15, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Andrea de BartolomeisFelice Iasevoli
Sep 20, 2018·Arquivos de neuro-psiquiatria·Laudiane Reis SantosMarise Bueno Zonta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here